A large pharmaceutical company headquartered in the US seeks to in-license assets and form partnerships with early-stage companies. The company’s investments and partnerships are varied in size, stage and structure. In addition to capital, early-stage partners may benefit from access to the company’s expertise and research capabilities. The firm will consider opportunities worldwide.
The company invests & partners diversely in therapeutic assets, including in Oncology, Neuroscience, Diabetes and Diabetes-Related Complications, Immunology, and Drug Delivery and Devices, in addition to discovery and research tools. Generally the firm has less interest in infectious diseases, ophthalmology, and rare diseases. The company focuses on assets that represent new biological modalities. The firm will also consider device investments on occasion. The firm will consider partnerships at any stage.
If you are interested in more information about this investor and other investors tracked by LSN, please email RESI@lifesciencenation.com.
Next Phase Newsletter 
Leave a comment